PT  - JOURNAL ARTICLE
AU  - Alexandria B. Boehm
AU  - Bridgette Hughes
AU  - Marlene K. Wolfe
AU  - Bradley J. White
AU  - Dorothea Duong
AU  - Vikram Chan-Herur
TI  - Regional replacement of SARS-CoV-2 variant BA.1 with BA.2 as observed through wastewater surveillance
AID  - 10.1101/2022.04.22.22274160
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.22.22274160
4099  - http://medrxiv.org/content/early/2022/04/25/2022.04.22.22274160.short
4100  - http://medrxiv.org/content/early/2022/04/25/2022.04.22.22274160.full
AB  - An understanding of circulating SARS-CoV-2 variants can inform pandemic response, vaccine development, disease epidemiology, and use of monoclonal antibody treatments. We developed custom assays targeting characteristic mutations in SARS-CoV-2 variants Omicron BA.1 and BA.2 and confirmed their sensitivity and specificity in silico and in vitro. We then applied these assays to daily wastewater solids samples from eight publicly owned treatment works in the greater Bay Area of California, USA, over four months to obtain a spatially and temporally intensive data set. We documented regional replacement of BA.1 with BA.2 in agreement with, and ahead of, clinical sequencing data. This study highlights the utility of wastewater surveillance for real time tracking of SARS-CoV-2 variant circulation.Synopsis Wastewater surveillance was used to document regional emergence of SARS-CoV-2 variant Omicron BA.2 ahead of clinical surveillance.Competing Interest StatementBH, DD, VC-H and BW are employees of Verily Life Sciences.Funding StatementThis study was funded by CDC-Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available through Stanford Digital Repository: https://doi.org/10.25740/cf848zx9249 https://doi.org/10.25740/cf848zx9249